Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (451-460 of 575) with videos related to

Pageof 58
Sort By:
Nutrition and Cancer|July 3, 2004
Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasiaLeslie Fischer, Chrysa Mahoney, A Robert Jeffcoat, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|May 1, 2013
Species differences in developmental toxicity of epoxiconazole and its relevance to humansSteffen Schneider, Thomas Hofmann, Stefan Stinchcombe, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2026
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)L W Martin, X Wang, D Kozono, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|January 5, 2021
Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patientsYufeng Wu, Zhensheng Liu, Dongfang Tang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 27, 2022
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNAThomas E Stinchcombe, Xiaofei Wang, Robert C Doebele, et al.
Cancer|November 24, 2024
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): AllianceApar K Ganti, Briant Fruth, Andreas Rimner, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2025
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United StatesHannah Le, Josh Coulter, Ken Culver, et al.
JCO Precision Oncology|January 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
JCO Precision Oncology|March 2, 2026
Erratum: Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
Science (New York, N.Y.)|October 14, 2021
Mitochondrial translation is required for sustained killing by cytotoxic T cellsMiriam Lisci, Philippa R Barton, Lyra O Randzavola, et al.
Pageof 58

Showing results (451-460 of 575) with videos related to

Sort By:
Pageof 58
Nutrition and Cancer|July 3, 2004
Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasiaLeslie Fischer, Chrysa Mahoney, A Robert Jeffcoat, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|May 1, 2013
Species differences in developmental toxicity of epoxiconazole and its relevance to humansSteffen Schneider, Thomas Hofmann, Stefan Stinchcombe, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2026
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)L W Martin, X Wang, D Kozono, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|January 5, 2021
Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patientsYufeng Wu, Zhensheng Liu, Dongfang Tang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 27, 2022
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNAThomas E Stinchcombe, Xiaofei Wang, Robert C Doebele, et al.
Cancer|November 24, 2024
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): AllianceApar K Ganti, Briant Fruth, Andreas Rimner, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2025
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United StatesHannah Le, Josh Coulter, Ken Culver, et al.
JCO Precision Oncology|January 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
JCO Precision Oncology|March 2, 2026
Erratum: Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
Science (New York, N.Y.)|October 14, 2021
Mitochondrial translation is required for sustained killing by cytotoxic T cellsMiriam Lisci, Philippa R Barton, Lyra O Randzavola, et al.
Pageof 58